Akoya Biosciences Stock (NASDAQ:AKYA)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$1.24

52W Range

$1.01 - $4.65

50D Avg

$1.73

200D Avg

$2.37

Market Cap

$61.97M

Avg Vol (3M)

$318.83K

Beta

1.33

Div Yield

-

AKYA Company Profile


Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

Show More

Industry

Medical - Instruments & Supplies

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

205

IPO Date

Apr 16, 2021

Website

AKYA Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 24Dec 23Dec 22
Consumables$28.26M$24.13M$18.38M
Service and other$28.64M$29.22M$17.21M
Product$53.03M$67.41M$57.65M
Standalone software products$940.00K$1.18M$636.00K
Service And Other$17.28M$18.93M-
Instruments$23.83M$42.09M$38.63M

Fiscal year ends in Dec 24 | Currency in USD

AKYA Financial Summary


Dec 24Dec 23Dec 22
Revenue$81.67M$96.63M$74.86M
Operating Income$-46.73M$-57.67M$-66.21M
Net Income$-55.37M$-63.32M$-70.64M
EBITDA$-46.73M$-45.63M$-58.81M
Basic EPS$-1.12$-1.43$-1.87
Diluted EPS$-1.12$-1.43$-1.87

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 14, 24 | 5:00 PM
Q2 24Aug 05, 24 | 5:00 PM
Q1 24May 17, 24 | 5:00 PM

Peer Comparison


TickerCompany
ATRAptarGroup, Inc.
PDEXPro-Dex, Inc.
LMATLeMaitre Vascular, Inc.
ICUIICU Medical, Inc.
COOThe Cooper Companies, Inc.
ATRCAtriCure, Inc.
HAEHaemonetics Corporation
ANGOAngioDynamics, Inc.
UTMDUtah Medical Products, Inc.